Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

This trial is testing a combination of two immunotherapy drugs — one that targets PD-1 (a brake on the immune system) and one that blocks blood vessel growth — before surgery in people with mouth cancer. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with oral squamous cell carcinoma (cancer of the mouth, tongue, or gums) at stage III or IVA - Your cancer's PD-L1 score (a measure of immune activity) is greater than 10 - Your cancer has not been treated with radiation to the head or neck before - Your general health is good enough to handle treatment (ECOG score 0–2) **You may NOT be eligible if...** - You have serious heart problems, a recent heart attack, or uncontrolled high blood pressure - You have a serious active infection - Your blood counts, liver, or kidney tests are abnormal - You are pregnant or breastfeeding - You are currently in another clinical trial Talk to your doctor to see if this trial is right for you.